SETDB1 and acute myeloid leukemia: The therapeutic potential of SETDB1 inhibition in AML was evidenced by the use of UNC0638, an H3K9me2/3 inhibitor that caused myeloid leukemia cell cytotoxicity, but also cKit+ hematopoietic stem cell line expansion in healthy bone marrow cells [116].